Department of Diagnostic Radiology & Nuclear Imaging, Division of Vascular & Interventional Radiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Department for Diagnostic & Interventional Radiology, University Medical Center Goettingen, Goettingen, 37075, Germany.
Future Oncol. 2022 May;18(14):1691-1703. doi: 10.2217/fon-2021-1487. Epub 2022 Feb 17.
To evaluate the utilization and outcomes of PD-1-directed immunotherapy (PD-1 IMT) for advanced hepatocellular carcinoma. Patients with advanced hepatocellular carcinoma receiving systemic therapy and PD-1 IMT (nivolumab/pembrolizumab) were included from the Flatiron database. Overall survival (OS) was evaluated using multivariable Cox models with the following subgroup analyses: patients with data on clinical performance and liver function and patients receiving tyrosine kinase inhibitors. n = 1770 patients were included (PD-1 IMT 19.3%). Overall, PD-1 IMT was associated with longer OS (hazard ratio [HR]: 0.57). This effect was robust across both subgroup analyses with HR: 0.72 (subgroup 1) and HR: 0.57 (subgroup 2). PD-1 IMT is increasingly used in clinical practice and associated with an OS benefit.
评估 PD-1 导向免疫治疗（PD-1 IMT）在晚期肝细胞癌中的应用和结局。从 Flatiron 数据库中纳入接受系统治疗和 PD-1 IMT（nivolumab/pembrolizumab）的晚期肝细胞癌患者。使用多变量 Cox 模型评估总生存期（OS），并进行以下亚组分析：有临床性能和肝功能数据的患者和接受酪氨酸激酶抑制剂治疗的患者。纳入 n=1770 例患者（PD-1 IMT 占 19.3%）。总体而言，PD-1 IMT 与更长的 OS 相关（风险比 [HR]：0.57）。这一效果在两个亚组分析中都很稳健，HR：0.72（亚组 1）和 HR：0.57（亚组 2）。PD-1 IMT 在临床实践中越来越多地被应用，并与 OS 获益相关。
